Lyra Therapeutics, Inc. (LYRA) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback